Pharma sector earnings to remain muted on weak US business, strong rupee
Pharma sector’s December quarter revenue is estimated to remain flat, while profits are likely to slip, owing to decline in US businesses and a sharp appreciation in rupee
New Delhi: The Indian pharma sector’s December-quarter revenue is estimated to remain flat, while profits are likely to slip owing to decline in US businesses and a sharp appreciation in rupee, says a report.
According to an Edelweiss Securities report, though the October-December quarter was “action packed”, earnings are likely to remain muted. “The pharma sector’s Q3FY18 (October-December quarter) revenue is estimated to remain flat year-on-year, while EBITDA and PAT are likely to decline 15% and 19%, respectively,” it noted. Ebitda stands for earnings before interest, tax, depreciation and amortization, and PAT stands for profit after tax.
The brokerage firm said weak US business and rupee appreciation against US dollar/Brazilian Real/Japanese Yen/ South African Rand are expected to drag earnings of Indian pharma companies. “US revenue expected to decline 11% year-on-year for the sector in constant currency (CC), as faster approvals, heightened competition and sustained pricing pressure to dent growth,” it said.
The report however noted that domestic sales are expected to grow 12% year-on-year on a low base. During the October-December period, the US Food and Drug Administration (USFDA) granted the highest-ever approvals in a single quarter with 246 nods.
“But faster approvals have led to heightened competition and pricing pressure, suppressing overall sector’s earnings,” it noted.
Going ahead, Edelweiss Securities expects the financial year 2017-18 is expected to be a “challenging year”. The sector continues to grapple with structural challenges like further customer consolidation and rising competition in the US.
Moreover, 2017-18 is likely to remain a disappointing year as appreciating rupee will be aggravated by the US and domestic challenges, it said. “Consensus downgrades continued, albeit tempered compared to previous quarters, with 2%/3% cut in FY18/19E earnings during October-December,” the report added.
- ICICI Bank postpones annual general meeting to 12 September
- India keen to join Russia in WTO case against US on metal tariffs
- Trai says users own their data, calls for stricter security rules
- Green tribunal asks Volkswagen to explain why polluting cars were not recalled
- In the US, dead malls spawn global tales
Editor's Picks »
- When do you need to update KYC details and how to do it
- Social Street partners with UK-based Works Limited to foster creativity in sports in India
- Is govt serious about protecting honest bankers?
- Entire global income is taxed in India for resident Indian status
- HUL’s Q1 results show demand is intact, but inflation poses a risk